At the Cold Spring Harbor Laboratory Conference on Blood-Brain Barriers, Dr. Sylvaine Guerit (Head of Preclinical Research) will…
Atti25 March 2025
Neuvasq Biotechnologies is a privately held research company focusing on the discovery and development of pioneering therapies to safeguard or rebuild central nervous system (CNS) barriers and improve neurovascular function for patients with severe neurological conditions.
More about our science
Advancing therapies to safeguard
or rebuild CNS barriers
and restore neurovascular function
Neuvasq Biotechnologies is a privately held research company focusing on the discovery and development of pioneering therapies to safeguard or rebuild central nervous system (CNS) barriers and improve neurovascular function for patients with severe neurological conditions.
More about our science
Join us in our mission to develop innovative therapies that truly impact patients’ lives
Latest insights and highlights
Latest insights and highlights
At the Cold Spring Harbor Laboratory Conference on Blood-Brain Barriers, Dr. Sylvaine Guerit (Head of Preclinical Research) will…
Atti25 March 2025
Neuvasq will participate in the Bio-Neuroscience Summit 2025 in Amsterdam, a dedicated forum for innovation, partnering and…
buro867 February 2025
Neuvasq Biotechnologies participated in the 2025 J.P. Morgan Healthcare Conference, a key event in the global…
buro8628 January 2025
Cookie policy